For instance, patients with lung cancer, colon cancer, or melanoma bearing BRAF V600E mutations all benefit from inhibitors targeting this mutation (Long et al., 2017; Planchard et al., 2017; Kopetz et al., 2019). This evidence concerns the gene BRAF and melanoma.